Matthew Sykes
Stock Analyst at Goldman Sachs
(3.86)
# 551
Out of 4,826 analysts
199
Total ratings
48.91%
Success rate
7.98%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $12.93 | +31.48% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $143.02 | +11.87% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.84 | +27.55% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $92.89 | +34.57% | 2 | Apr 29, 2025 | |
| AVTR Avantor | Downgrades: Neutral | $23 → $14 | $12.64 | +10.76% | 6 | Apr 29, 2025 | |
| DHR Danaher | Maintains: Buy | $260 → $240 | $197.40 | +21.58% | 5 | Apr 23, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $18 → $14 | $7.68 | +82.29% | 11 | Apr 17, 2025 | |
| CDNA CareDx | Maintains: Buy | $34 → $26 | $15.19 | +71.22% | 10 | Apr 17, 2025 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | $190 → $170 | $119.52 | +42.24% | 4 | Mar 21, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $22 → $11 | $5.93 | +85.50% | 3 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $44.05 | +27.13% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $66.16 | +20.92% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.10 | +36.36% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $157.23 | +20.84% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.68 | +155.55% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.12 | +100.95% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $31.32 | +18.14% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $60 | $40.72 | +47.35% | 4 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $53.32 | +21.91% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $152.27 | +64.18% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $14 | $8.61 | +62.70% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $35.98 | +52.86% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.83 | +311.66% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,091.13 | +19.14% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $6.92 | +73.41% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $422.62 | +51.44% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $3.80 | +163.50% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $108.37 | +33.80% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $42.80 | - | 5 | Dec 7, 2023 |
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $12.93
Upside: +31.48%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $143.02
Upside: +11.87%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.84
Upside: +27.55%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $92.89
Upside: +34.57%
Avantor
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.64
Upside: +10.76%
Danaher
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $197.40
Upside: +21.58%
Myriad Genetics
Apr 17, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $7.68
Upside: +82.29%
CareDx
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $15.19
Upside: +71.22%
Charles River Laboratories International
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $119.52
Upside: +42.24%
Fortrea Holdings
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $11
Current: $5.93
Upside: +85.50%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $44.05
Upside: +27.13%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $66.16
Upside: +20.92%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.10
Upside: +36.36%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $157.23
Upside: +20.84%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.68
Upside: +155.55%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.12
Upside: +100.95%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $31.32
Upside: +18.14%
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $40.72
Upside: +47.35%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $53.32
Upside: +21.91%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $152.27
Upside: +64.18%
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $8.61
Upside: +62.70%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $35.98
Upside: +52.86%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.83
Upside: +311.66%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,091.13
Upside: +19.14%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $6.92
Upside: +73.41%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $422.62
Upside: +51.44%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $3.80
Upside: +163.50%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $108.37
Upside: +33.80%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $42.80
Upside: -